Upstream Bio’s (UPB) Buy Rating Reiterated at HC Wainwright

Upstream Bio (NASDAQ:UPB)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $36.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 449.62% from the stock’s previous close.

Several other equities research analysts have also weighed in on the company. Truist Financial dropped their target price on Upstream Bio to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Mizuho reduced their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Wall Street Zen lowered shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. increased their price objective on shares of Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. Finally, Weiss Ratings upgraded shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $29.67.

Upstream Bio Trading Down 1.1%

Shares of Upstream Bio stock opened at $6.55 on Wednesday. The business’s 50 day simple moving average is $6.96 and its 200-day simple moving average is $7.97. The stock has a market capitalization of $358.74 million, a price-to-earnings ratio of -2.26 and a beta of 1.28. Upstream Bio has a twelve month low of $5.85 and a twelve month high of $33.68.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%.The business had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.56 million. Sell-side analysts predict that Upstream Bio will post -2.86 earnings per share for the current year.

Institutional Trading of Upstream Bio

Hedge funds have recently added to or reduced their stakes in the business. UBS Group AG grew its stake in shares of Upstream Bio by 563.4% in the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock worth $49,039,000 after purchasing an additional 1,533,972 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Upstream Bio during the second quarter valued at $3,450,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of Upstream Bio during the first quarter valued at about $1,666,000. SEB Asset Management AB bought a new stake in shares of Upstream Bio during the first quarter valued at about $7,906,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in Upstream Bio in the second quarter worth about $6,472,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.